Processing

Please wait...

Settings

Settings

Goto Application

Offices all Languages en Stemming true Single Family Member true

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents

Full Query

IC:A61K39/00

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.WO/2020/232527CRIMEAN-CONGO HEMORRHAGIC FEVER VIRUS IMMUNOGENIC COMPOSITIONS
WO 26.11.2020
Int.Class C12N 15/40
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
31Genes encoding microbial proteins, e.g. enterotoxins
33Genes encoding viral proteins
40Proteins from RNA viruses, e.g. flaviviruses
Appl.No PCT/CA2019/051592 Applicant UNIVERSITÉ LAVAL Inventor KOBINGER, Gary
The present disclosure relates to DNA vaccines against Crimean-Congo Hemorrhagic Fever (CCHF) virus. The present disclosure also relates to CCHF virus sequences and their use for vaccination such as DNA vaccination. The present disclosure more particularly relates to artificial nucleic acid molecules that are able to encode a CCHF polypeptide of an infectious CCHF virus, a fragment or a variant thereof. The nucleic acid molecules of the present application are formulated as immunogenic compositions.
2.WO/2020/234387IL-2/IL-15Rßy AGONIST DOSING REGIMENS FOR TREATING CANCER OR INFECTIOUS DISEASES
WO 26.11.2020
Int.Class A61K 38/17
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17from animals; from humans
Appl.No PCT/EP2020/064132 Applicant CYTUNE PHARMA Inventor MOEBIUS, Ulrich
The present invention provides pulsed cyclic administration regimes and pulsed administration regimes for interleukin-2/interleukin-15 receptor βɣ (IL-2/IL-15Rβɣ) agonists for treating or managing cancer or infectious diseases in human patients. The administration regimes inter alia involve daily administration of IL-2/IL-15Rβɣ agonists on 2, 3 or 4 consecutive days followed by days without administration.
3.WO/2020/236667METHODS OF TREATING CANCER
WO 26.11.2020
Int.Class A61K 31/427
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
41having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
425Thiazoles
427not condensed and containing further heterocyclic rings
Appl.No PCT/US2020/033311 Applicant GB006, INC. Inventor DUPONT, Jakob
Disclosed herein are methods for treating cancer by administration to a patient in need thereof, an effective amount of (Z)-4-(5-((3-benzyl-4-oxo-2-thioxothiazolidin-5-ylidene) methyl) furan-2-yl) benzoic acid or pharmaceutically acceptable salts thereof and pembrolizumab. In some embodiments, the choline salt Z)-4-(5-((3-benzyl-4-oxo-2-thioxothiazolidin-5-ylidene) methyl) furan-2-yl) benzoic acid is administered. In some embodiments, the patient has a solid tumor.
4.WO/2020/237027COMBINATION OF A TLR7 MODULATING COMPOUND AND AN HIV VACCINE
WO 26.11.2020
Int.Class A61K 39/12
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
Appl.No PCT/US2020/033959 Applicant GILEAD SCIENCES, INC. Inventor GELEZIUNAS, Romas
The present disclosure describes methods, compositions, and kits related to the combination of a TLR7 modulating compound and an HIV vaccine. The combination can be used in a method of treating or preventing an HIV infection in a human.
5.WO/2020/236116UNIVERSAL CRIMEAN CONGO HAEMORRHAGIC FEVER VIRUS (CCHFV) VACCINE
WO 26.11.2020
Int.Class A61K 39/12
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
Appl.No PCT/TR2020/050428 Applicant ÖZDARENDELİ, Aykut Inventor ÖZDARENDELİ, Aykut
This invention relates to universal Crimean Congo Haemorrhagic Fever Virus (CCHFV) vaccine. This vaccine comprising viral vector with Bioinformatically Generated Conserved Antigen (BGCA) of CCHFV which evoke immune responses against CCHFV, or diseases triggered by infection of CCHFV.
6.WO/2020/236626METHODS AND SYSTEMS FOR TREATING MICROBIAL DISEASE
WO 26.11.2020
Int.Class A61K 39/395
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
Appl.No PCT/US2020/033210 Applicant HERZLINGER, George A. Inventor HERZLINGER, George A.
The present disclosure provides methods and systems for treating a biological fluid of a subject suffering from a microbial infection (e.g., a drug-resistant microbial infection). In some embodiments, these methods and systems involve a complement receptor immobilized on, or otherwise associated with a polymer substrate, for example, high surface area particles, membranes, hollow fibers, and/or other porous or non-porous media. In other embodiments, the methods and systems involve a complement receptor present in a dialysate used in a dialyzer for extracting pathogens out of a biological fluid, for example, the blood of a patient.
7.WO/2020/237246LIVE ATTENUATED NON-TRANSMISSIBLE VACCINES
WO 26.11.2020
Int.Class A61K 39/12
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
Appl.No PCT/US2020/034596 Applicant UNIVERSITY OF MARYLAND, BALTIMORE Inventor TENNANT, Sharon
The present invention provides genetically modified microorganisms with reduced transmissibility, wherein the microorganism has been genetically modified to express a single stranded binding protein (SSB) regulated by an arabinose responsive promoter, wherein the microorganism has a reduced growth capacity in the absence of arabinose.
8.WO/2020/233685INTEIN-MEDIATED NANO-CARRIER AND APPLICATION THEREOF, AND NANO PREPARATION CAPABLE OF SIMULTANEOUSLY DELIVERING ANTIGEN AND IMMUNOPOTENTIATOR
WO 26.11.2020
Int.Class C07K 19/00
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
19Hybrid peptides
Appl.No PCT/CN2020/091636 Applicant GUANGZHOU WOMEN AND CHILDREN'S MEDICAL CENTER Inventor TANG, Shubing
Provided are an intein-mediated nano-carrier and an application thereof. The nano-carrier is constructed by the following steps: introducing three tandem proteins, i.e., intN, gb1 and halo, into a C-terminal of an encapsulin protein by using a gene fusion method so as to form a recombinant protein encapsulin-intN-gb1-halo; subjecting 60 recombinant protein monomers to self-assembly so as to obtain nano-particles, exposed intN-gb1-halo thereof being taken as a universal "adapter", and after the adapter is mixed with cargo recombinant proteins gb1-intC and cargo, performing molecular recombination under the assistance of DTT; and subjecting intein to self-excision to form by-products intN-gb1-halo and gb1-intC, and subjecting encapsulin and the cargo to covalent coupling so as to produce a target product encapsulin-cargo. Also provided is a nano preparation capable of simultaneously delivering an antigen and an immunopotentiator, which formed by fusing an N-terminal of ferritin with a C-terminal of a connector gbl-intein to form a recombinant protein gbl-inteinc-ferrtin, performing self-assembly to obtain 24 polymers to form nanoparticles, fusing a C-terminal of an exogenous protein with an N-terminal of the intein to form the recombinant protein, enabling the N-terminal of the intein to specifically recognize and excise the ferritin exposed on the surface of the nanoparticles, and performing covalent cross-linking of the exogenous protein and the ferritin, wherein the exogenous protein is an immunopotentiator, or an antigen, or a combination of the immunopotentiator and the antigen.
9.WO/2020/233695NOVEL ANTI-HEPATITIS B VIRUS ANTIBODY AND USES THEREOF
WO 26.11.2020
Int.Class C07K 16/08
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
08against material from viruses
Appl.No PCT/CN2020/091739 Applicant XIAMEN UNIVERSITY Inventor LUO, Wenxin
Disclosed are antibodies to anti-hepatitis B surface antigen (HBsAg) (especially humanized antibodies), nucleic acid molecules encoding same, methods for preparing same, and pharmaceutical compositions containing same. The antibodies have higher affinity for HBsAg at neutral pH than at acidic pH, thereby significantly enhancing the virus clearance efficiency and prolonging the virus inhibition time. The antibodies and the pharmaceutical compositions can be used for preventing and/or treating HBV infections or diseases related to HBV infections (e.g., hepatitis B), for neutralizing the virulence of HBV in a subject (e.g., a human), for reducing the serum level of HBV DNA and/or HBsAg in the body of the subject, or for activating the humoral immune response of the subject (e.g., a chronic HBV infected or chronic hepatitis B patient) against HBV.
10.WO/2020/233715ANTI-HEPATITIS B VIRUS ANTIBODIES AND USE THEREOF
WO 26.11.2020
Int.Class C07K 16/08
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
08against material from viruses
Appl.No PCT/CN2020/091890 Applicant XIAMEN UNIVERSITY Inventor LUO, Wenxin
Antibodies (especially humanized antibodies) against the hepatitis B surface antigen (HBsAg), a nucleic acid molecule encoding same, a method for preparing same, and a pharmaceutical composition containing same. The anti-HBsAg antibodies have a higher binding affinity to HBsAg at a neutral pH than at an acidic pH, thereby significantly enhancing virus clearance efficiency and prolonging virus inhibition time. The antibodies and pharmaceutical composition may be used to prevent and/or treat HBV infections or diseases related to HBV infection (such as hepatitis B) for use in neutralizing the virulence of HBV in the body of a subject (such as a human) to reduce a serum level of HBV DNA and/or HBsAg in the body of the subject, or to activate a humoral immune response of a subject (such as a person infected with chronic HBV or a patient who has chronic hepatitis B) against HBV.